Practice of nursing; providing for independent prescriptive authority of Advanced Practice Registered Nurses who meet certain requirements; modifying various provisions of the Oklahoma Pharmacy Act, the Oklahoma Nursing Practice Act, and the Uniform Controlled Dangerous Substances Act; effective date.
HB2298 expands the authority of certain Advanced Practice Registered Nurses (APRNs) in Oklahoma to prescribe medications independently after meeting specified experience and licensing requirements. Under the bill, Certified Nurse Practitioners, Clinical Nurse Specialists, and Certified Nurse-Midwives may apply for independent prescriptive authority after completing at least 6,240 supervised clinical practice hours with prescriptive authority. The authority lasts with the APRN license, may be renewed, and can be suspended or revoked by the Oklahoma Board of Nursing for violations. The bill also authorizes the Board to charge application review fees and requires malpractice coverage or proof of financial responsibility at specified minimum limits.
The measure also revises supervision rules for APRNs who have not obtained independent prescriptive authority. It sets eligibility standards for supervising physicians, requires written supervision agreements, allows reasonable supervision fees under defined conditions, requires notice of physician unavailability, mandates reporting of changes in the supervisory relationship, and directs the medical licensing boards to create uniform supervision rules and publish lists of physicians available to supervise APRNs. In addition, the bill requires advertising rules so APRNs clearly identify themselves as APRNs and do not imply they are physicians.
HB2298 amends multiple statutes, including provisions of the Oklahoma Nursing Practice Act, the Oklahoma Pharmacy Act, and the Uniform Controlled Dangerous Substances Act. It updates definitions, clarifies prescriptive authority and endorsement pathways for APRNs licensed in other states, and aligns controlled-substance prescribing rules with the new independent authority framework. The bill also preserves limits on controlled dangerous substances for APRNs who have not obtained independent authority and keeps certain CRNA anesthesia-related rules separate.
The general sentiment reflected in the voting history is supportive but not unanimous. The bill advanced through committees and floor votes with clear majorities, including strong committee approvals and successful veto overrides in both chambers, indicating broad legislative backing for expanding APRN practice authority. At the same time, the nontrivial number of no votes in the House and Senate suggests meaningful reservations remained.
The main points of contention appear to center on scope of practice, physician oversight, and patient safety. Supporters likely viewed the bill as a workforce and access-to-care measure that modernizes APRN practice and reduces unnecessary supervision barriers, while critics likely focused on whether independent prescribing should be allowed and whether the supervision, insurance, and advertising safeguards are sufficient. The supervision-fee provisions, physician eligibility requirements, and limits on controlled-substance prescribing were likely intended to address those concerns.
HB2298 changes Oklahoma law by creating a pathway for certain APRNs to obtain independent prescriptive authority, while also tightening and standardizing rules for supervised APRN prescribing. It amends the Nursing Practice Act, Pharmacy Act, and Controlled Dangerous Substances Act to recognize independent APRN prescribing for qualifying nurse practitioners, clinical nurse specialists, and nurse-midwives, and to update related definitions, endorsement procedures, and pharmacy dispensing rules. It also imposes malpractice insurance requirements, supervision agreement requirements, and new rulemaking duties on the Oklahoma Board of Nursing, the State Board of Medical Licensure and Supervision, and the State Board of Osteopathic Examiners.
The bill appears to have had generally favorable legislative momentum, passing committees and floor votes in both chambers and later surviving veto override votes. The vote margins suggest substantial bipartisan support for expanding APRN authority, though not overwhelming consensus. The presence of significant minority opposition in several votes indicates that the bill remained controversial, particularly among lawmakers concerned about the scope of independent practice and the role of physician supervision.
The central controversy is the balance between expanding access to care through APRN independence and preserving physician oversight of prescribing. Opponents likely objected to allowing APRNs to prescribe independently after meeting experience thresholds, while supporters likely argued that the bill preserves safeguards through licensure standards, malpractice coverage, and board discipline. Additional contention likely involved supervision fees, the required written supervision agreements, the limits on controlled substances, and whether the advertising restrictions and disclosure rules are enough to prevent confusion about APRN credentials.